Home › Trials › NCT07321873

JNJ-88545223 for adults with active psoriatic arthritis

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis

Phase 2 Interventional Janssen Research & Development, LLC · NCT07321873

This trial will test whether the medicine JNJ-88545223 can reduce joint and skin symptoms in adults with active psoriatic arthritis compared with a placebo.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment240 (estimated)
Ages18 Years and up
SexAll
SponsorJanssen Research & Development, LLC Industry-sponsored
Locations40 sites (Searcy, Arkansas and 39 other locations)
Trial IDNCT07321873 on ClinicalTrials.gov

What this trial studies

This is a phase 2, placebo-controlled interventional trial of JNJ-88545223 in adults with active psoriatic arthritis. Enrolled participants must have had PsA for at least 3 months, meet CASPAR criteria, have at least 3 swollen and 3 tender joints, and a CRP ≥ 0.1 mg/dL; they must also have active plaque psoriasis or nail changes. Participants will receive either JNJ-88545223 or a matching placebo and will be monitored for changes in joint and skin signs and symptoms and for safety. The study is being conducted at multiple U.S. clinical sites.

Who should consider this trial

Good fit: Adults with a confirmed diagnosis of psoriatic arthritis meeting CASPAR, active disease with ≥3 swollen and ≥3 tender joints, CRP ≥0.1 mg/dL, and at least one qualifying psoriasis feature (≥2 cm plaque or nail changes) are ideal candidates.

Not a fit: People without active PsA by the study criteria, pregnant women, or those who do not meet the joint-count or laboratory requirements are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, JNJ-88545223 could reduce joint pain and swelling and improve skin symptoms for people with active PsA.

How similar studies have performed: Other randomized, placebo-controlled trials of targeted therapies for psoriatic arthritis have produced meaningful symptom improvements, but the specific effects of JNJ-88545223 are still being tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening
* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) greater than or equal to (\>=) 0.1 milligrams per deciliter (mg/dL) at screening from the central laboratory
* Have \>= 1 of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
* Have active plaque psoriasis with at least one psoriatic plaque of \>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention

Exclusion Criteria:

* Has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (except PsA), psychiatric, genitourinary, or metabolic disturbances
* Has suspected or known allergies, hypersensitivity, or intolerance to JNJ-88545223 or excipients used in the investigational medicinal product (IMP), including placebo (JNJ-88545223 investigator's brochure); or has a history of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
* Has fibromyalgia or osteoarthritis symptoms that, in the opinion of the investigator, would have potential to interfere with efficacy assessments
* Currently has a malignancy or has a history of malignancy within 5 years prior to screening

Where this trial is running

Searcy, Arkansas and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Arthritis, Psoriatic
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.